The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says. GLP-1 weight ...

SGLT-2i是一类因其减重效果而被认为对MASLD治疗有益的抗糖尿病药物。尽管评估SGLT-2i对MASH影响的随机对照试验（RCT）仍在进行中，但已有临床前研究表明SGLT-2i能够减少肝脏炎症，并降低MASLD患者的肝事件风险。此外，由于MAS ...

A new study found that the weight loss drug Ozempic can help reduce a stroke patient’s risk of a heart attack or death. The ...

2型糖尿病是全球范围内常见的慢性疾病，其不仅影响血糖控制，还与多种并发症相关，包括心血管疾病和神经退行性疾病。SGLT2i是一类通过抑制肾小管对葡萄糖的重吸收来降低血糖水平的药物。近年来，有研究表明SGLT2i除了降糖作用外，还可能改善 线粒体 ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

研究提供了II类证据，表明SGLT2i可能与2型糖尿病患者痴呆/PD风险降低有关，SGLT2i可能对2型糖尿病患者有神经保护作用。 随着 ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

药企到了关键时期，如果销售额无法覆盖研发投入，看不到商业化的希望，药企会早早将临床早期的管线以几千万美元的首付款授权给海外药企。近两年，海外BD“不得已的活跃”，成为药企的生存手段。能BD出海的管线，一定是存在国际竞争力的。这些管线在临床早期就被海外 ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.